Outlook Therapeutics Regains Nasdaq Compliance as FDA Schedules ONS-5010 Verdict for July

Outlook Therapeutics stock doubles YTD after FDA accepts eye-drug application for fast-track review and Nasdaq delisting threat is removed.

The biotech has pulled off a double act in recent weeks: it has shown the US regulator that its resubmitted eye-drug application is worthy of a full review while also convincing the Nasdaq that it deserves to keep its listing. For Outlook Therapeutics, the combination has sparked a rally that has more than doubled the stock since the start of the year.

Shares closed Thursday at $1.72, bringing the year-to-date gain to roughly 160 percent. Over 30 days the advance is almost 93 percent — a run that has pushed the market capitalisation to around €190 million. But the ride remains choppy. On the day the company confirmed it had met the Nasdaq minimum bid-price requirement, the stock actually slipped about 3.5 percent, a reminder that volatility runs at an annualised 183 percent.

The Nasdaq issue is now off the table. Outlook Therapeutics logged ten consecutive trading sessions with a closing price of at least $1.00, satisfying the exchange's continued-listing standard and removing the spectre of a delisting that had hung over the name. That operational relief is welcome, yet the real catalyst is the calendar.

The FDA has accepted the company's resubmitted biologics license application for ONS-5010, the branded formulation of bevacizumab known as LYTENAVA that targets wet age-related macular degeneration. The agency granted the filing a Class 1 review — the faster of two review pathways — and set a target decision date of July 29, 2026. A green light would make ONS-5010 the first FDA-approved ophthalmic formulation of bevacizumab for wet AMD, a condition that today is largely treated with off-label, pharmacy-compounded versions of the drug. In Europe, where the medicine already has approval, Outlook has begun commercial rollout in Germany, Austria and the United Kingdom.

The market is pricing in optimism. The stock now trades more than 100 percent above its 50-day moving average of $0.86 and roughly 85 percent above the 200-day average of $0.93. From the 52-week low of $0.16 touched in March 2026, the shares have nearly decupled. The relative strength index sits at 67.8 — approaching but not yet in overbought territory. Still, the current price is 42 percent below the 52-week high of $2.97 from August 2025, suggesting room for further upside if the FDA outcome is favourable.

Competition is intensifying in the retinal-disease space. Biocon Biologics has released positive phase 3 data for its own anti-VEGF candidate Yesafili, while Teva Pharmaceutical Industries and Samsung Bioepis have struck a deal to commercialise OPUVIZ in Canada. These moves underscore the pressure on Outlook to deliver a first-mover advantage in the US.

For now, the entire valuation hinges on a single binary event. With the Nasdaq compliance secured and the FDA review clock ticking, the stock is effectively a two-way bet on the judgement that arrives on July 29.